R1 RCM Inc

R1 RCM, Inc. engages in the provision of revenue cycle management to healthcare providers. It offers end-to-end, modular revenue cycle, and physician advisory services. The company was founded by Mary Ann Tolan and J. Michael Cline in July 2003 and is headquartered in Murray, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

R1 RCM Inc (RCM) posts strong Q4 results, eyes Cloudmed growth

R1 RCM Inc (RCM) delivered robust financial performance in Q4 2022, focusing on operational excellence, technology investments, and customer engagement. Challenges include integration efforts and seasonality affecting incentive fees. The company is poised for growth with opportunities in Cloudmed expansion and AI utilization.

R1 RCM Inc (RCM) reports strong Q1 results and growth opportunities

R1 RCM Inc (RCM) delivered strong Q1 results, with a focus on operational improvements, robust Cloudmed growth, and positive financial outlook for 2023.
The company showcased resilience in stable patient self-pay trends, improving payer reimbursement timelines, and strategic capacity for onboarding new NPR, positioning itself for continued success.
Challenges include industry financial pressures, sustaining growth in legacy business, and managing operational costs effectively, requiring strategic adaptation and continuous innovation.
Opportunities lie in pipeline visibility for deals, sequential EBITDA growth, integration of Cloudmed capabilities, and strategic onboarding plans, offering avenues for expansion and profitability.

R1 RCM Inc reports robust Q2 earnings, eyes growth opportunities

R1 RCM Inc's Q2 performance was strong, with a focus on technology and operational enhancements. Challenges include revenue adjustments and workforce implications of automation. Opportunities lie in improved payer dynamics and growth through physician market focus and cross-selling.

R1 RCM Inc reports robust Q3 performance and eyes growth

R1 RCM Inc's Q3 earnings call highlighted strong financial performance, strategic priorities, and challenges in pediatric contracts and integration issues.
The company's focus on revenue optimization, leveraging technology, and partnership with Microsoft positions it well for growth opportunities within the customer base and offshoring initiatives.
While facing challenges in deal timings and debt repayment, R1 RCM Inc's emphasis on operational metrics, customer relationships, and workforce management presents avenues for continued success and industry leadership.

R1 RCM Inc reports robust Q4 earnings, eyes growth opportunities

R1 RCM Inc's Q4 2023 earnings call highlighted strong financial performance, strategic objectives for 2023, and a confident outlook for sustainable growth and shareholder value creation.
The company's emphasis on customer-centricity, AI integration, and operational efficiency underscores its strengths in revenue growth and market positioning.
While facing challenges in credit allowances and customer health, R1 RCM Inc aims to leverage opportunities in reduced costs, synergies from acquisitions, and strategic sales to drive future growth.

R1 RCM reports resilient Q1 performance post-cyberattack, eyes growth

R1 RCM showcased resilience in Q1 2024 despite the Change Healthcare cyberattack, focusing on growth strategies, operational excellence, and technology innovation.
The company faces challenges from the cyberattack impact on KPIs and vendor changes but sees opportunities in the managed care environment and customer engagement.
Overall, R1 RCM remains optimistic about transforming the industry through technology and expertise, with a strong market demand for its solutions.

R1 RCM Inc reports robust Q2 earnings amidst cyberattack challenges

R1 RCM Inc's Q2 2024 earnings call showcased strong financial performance, operational resilience in the face of cyberattacks, and a strategic focus on growth initiatives. The company faces challenges related to pending transactions and cyberattack impacts but sees opportunities in expanding its platform and leveraging technology for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

R1 RCM serves as a revenue cycle management partner for hospitals and healthcare systems regardless of the payment models, patient engagement strategies, or settings of care. The company uses a proven operating model based on the R1 Performance StackSM designed to fit seamlessly into any healthcare organization’s infrastructure and to enhance the patient experience, improve provider economics, and provide revenue predictability. R1 RCM was founded on 2003 and is based in Chicago, Illinois.

Company Enters 10-Year Agreement to Provide Comprehensive Revenue Cycle Management Services to Providence Company to Release Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Outlook on February 27, 2024 MURRAY, Utah, Jan. 17, 2024 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that it has completed its previously announced acquisition of Acclara from Providence, one of the nation's largest health systems. In addition, the Company announced that it expects to release financial results for the fourth quarter and full year ended December 31, 2023, and its 2024 outlook and will host a conference call at 8:00 a.m.

R1 RCM Completes Acquisition of Acclara, Providence's Modular Services Business

LOS ANGELES, CA / ACCESSWIRE / January 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("RCM" or "the Company") (NASDAQ:RCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

Allegro MicroSystems

Calix

Celsius Holdings

Civitas Resources

Darling Ingredients

Frontier Communications Corporation

HealthEquity

Interactive Brokers

Iridium Communications

Jazz Pharmaceuticals

Lantheus Holdings

MP Materials

Matador Resources

Perrigo

Teradata

TKO Group Holdings Inc

United Therapeutics

Valaris Ltd

Essential Utilities

When investors think about whether to increase their exposure beyond the big companies that grab most of the headlines in the financial media, they are likely to look at small-cap stocks first. After all, the sky's the limit.

20 midcap stocks with 2024 upside ranging up to 62%, according to analysts

MURRAY, Utah, Dec. 21, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2023, at 10:30am ET.

R1 RCM to Present at the 42nd Annual J.P. Morgan Healthcare Conference

LOS ANGELES, CA / ACCESSWIRE / December 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("RCM" or "the Company") (NASDAQ:RCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

NEW YORK , Dec. 18, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of R1 RCM Inc. ("RCM" or the "Company") (NASDAQ: RCM). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of R1 RCM Inc. - RCM

LOS ANGELES, CA / ACCESSWIRE / December 18, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("RCM" or "the Company") (NASDAQ:RCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / December 13, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("RCM" or "the Company") (NASDAQ:RCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

Acquisition of Providence's Current Modular Services Business Accompanied by 10-Year Agreement to Provide Comprehensive Revenue Cycle Management Services

R1 RCM to Acquire Acclara

As Expected, No Material Impact on 2023 Financial Results; No Impact on Cash, Business Operations or 2023 Outlook As Expected, No Material Impact on 2023 Financial Results; No Impact on Cash, Business Operations or 2023 Outlook

R1 Completes Restatement of Previously Issued Financial Statements

LOS ANGELES, CA / ACCESSWIRE / December 3, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("RCM" or "the Company") (NASDAQ:RCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, continues its investigation on behalf of R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your RCM investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of R1 RCM Inc. (RCM) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz continues its investigation of R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On October 16, 2023, Jehoshaphat Research published a report alleging, among other things, that RCM's “revenues and profits are grossly overstated,” that certain reported revenue growth.

The Law Offices of Frank R. Cruz Continues Investigation of R1 RCM Inc. (RCM) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith continues its investigation on behalf of R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM) investors concerning the Company's possible violations of federal securities laws. On October 16, 2023, Jehoshaphat Research published a report alleging, among other things, that RCM's “revenues and profits are grossly overstated,” that certain reported revenue growth has been “derived from inputs based on assumptions about future collections.

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of R1 RCM Inc. (RCM) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / November 21, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("RCM" or "the Company") (NASDAQ:RCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

MURRAY, Utah, Nov. 17, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced that, as anticipated, it received a letter from Nasdaq's Listing Qualifications Department indicating that, as a result of the Company's delay in filing its Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2023 (the “Form 10-Q”), the Company no longer complies with the continued listing requirements under Nasdaq Listing Rule 5250(c)(1), which requires Nasdaq-listed companies to timely file all periodic reports with the Securities and Exchange Commission (the “Commission”). On November 13, 2023, the Company filed with the Commission a Notification of Late Filing on Form 12b-25 with respect to the Form 10-Q as a result of its determination to restate certain of its previously issued financial statements.

R1 RCM Receives Notice of Filing Delinquency from Nasdaq

No Material Impact on 2023 Financial Results; Reaffirms 2023 Outlook No Impact on Cash or Business Operations MURRAY, Utah, Nov. 13, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM) (“R1”), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced its decision to restate its previously issued financial statements for the years ended December 31, 2022 and 2021 and interim periods, as well as for the first two quarters of 2023. Immediately prior to the scheduled filing of its Form 10-Q for the third quarter 2023, R1 identified errors related to the accounting for certain acquiree compensation costs (e.g.

R1 RCM to Restate Certain Previously Issued Financial Statements Due to Errors in Accounting for Expenses Associated with Historical Acquisitions

Envestnet

Hyster-Yale Materials Handling

Joby Aviation

Mister Car Wash

QUALCOMM

TransDigm

Can the S&P 500 SPX squeak by with another winning session? Watch for comments from Fed Chairman Jerome Powell to come and another bond auction.

A flying taxi company and other stock bets that will work even in a tough market ahead, says this hedge-fund manager

NEW YORK--(BUSINESS WIRE)---- $RCM #classactionlawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against R1 RCM Inc. (“RCM” or the “Company”) (NASDAQ: RCM). The investigation concerns whether RCM and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. On October 16, 2023, a market analyst and investment firm, Jehoshaphat Research released a report on RCM, claiming that the Company's financial accounting has been misrepresenta.

Kirby McInerney LLP Continues Investigation of Shareholder Claims Against R1 RCM Inc. (RCM)

R1 RCM Inc. (NASDAQ:RCM ) Q3 2023 Earnings Conference Call November 2, 2023 8:00 AM ET Company Participants Evan Smith - Investor Relations Lee Rivas - Chief Executive Officer Jennifer Williams - Chief Financial Officer Conference Call Participants Charles Rhyee - TD Cowen Jailendra Singh - Truist Securities Daniel Grosslight - Citigroup Glen Santangelo - Jefferies Elizabeth Anderson - Evercore ISI Sean Dodge - RBC Capital Markets Jack Wallace - Guggenheim Securities George Hill - Deutsche Bank Craig Hettenbach - Morgan Stanley Jeff Garro - Stephens Richard Close - Canaccord Genuity Operator Thank you for standing by. My name is Sydney and I will be your conference operator today.

R1 RCM Inc. (RCM) Q3 2023 Earnings Call Transcript

While the top- and bottom-line numbers for R1 RCM Inc. (RCM) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

R1 RCM Inc. (RCM) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates

R1 launches its first LLM-based application to improve physician coding quality R1 launches its first LLM-based application to improve physician coding quality

R1 RCM expands collaboration with Microsoft to accelerate integration of Azure OpenAI Service across the R1 enterprise

MURRAY, Utah, Nov. 02, 2023 (GLOBE NEWSWIRE) -- R1 RCM Inc. (NASDAQ: RCM), a leading provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers, today announced results for the three months ended September 30, 2023.

R1 RCM Reports Third Quarter 2023 Results

NEW YORK , Oct. 23, 2023 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of R1 RCM Inc. (NASDAQ: RCM) resulting from allegations that R1 may have issued materially misleading business information to the investing public. SO WHAT: If you purchased R1 RCM securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

RCM INVESTOR NOTICE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages R1 RCM Inc. Investors to Inquire About Securities Class Action Investigation - RCM

LOS ANGELES, CA / ACCESSWIRE / October 22, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of R1 RCM Inc. ("RCM" or "the Company") (NASDAQ:RCM) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against R1 RCM Inc. and Encourages Investors with Losses to Contact the Firm

News for R1 RCM Inc Stock (RCM)